logo-loader
viewTissue Regenix Group PLC

Tissue Regenix focused on securing further strategic partnerships

"We are now in the position of really trying to kick on in 2018'', Couldwell says

Steve Couldwell, chief executive of Tissue Regenix PLC (LON:TRX), tells Proactive that 2017 has been a year of transformation, boosted by the acquisition of CellRight.

“That was the transformation the company really needed, and the integration of that business has gone extremely well ... we are now in the position of really trying to kick on in 2018'', Couldwell says.

Since the end of the reporting period, the group's announced strategic partnerships with ARMS Medical for DermaPure and with Arthrex for the distribution of CellRight’s ‘BioRinse’ portfolio.

Quick facts: Tissue Regenix Group PLC

Price: 0.32 GBX

AIM:TRX
Market: AIM
Market Cap: £22.51 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: FTSE 100 heads higher as markets welcome easing of restrictions

Headlines from the Proactive UK newsroom. The FTSE 100 rose 21 points to 6,957 as markets welcomed more easing of coronavirus lockdown measures across Europe despite some confusion in the UK. UK prime minister Boris Johnson, though, is being pressed for more clarity on the relaxation of UK...

on 11/5/20

2 min read